Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00413400 · ClinicalTrials.gov registry record · NA

Study of TNF-Antagonism in the Metabolic Syndrome (II)

A NA study, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT00413400: Completed NA study, sponsored by Massachusetts General Hospital.

NCT00413400 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00413400, a NA study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.

Primary Outcome

As a measure of C-reactive protein (CRP), which is an inflammatory marker, Log10 of the CRP at 6 months is reported

Interventions

  • DRUG Placebo
  • DRUG Etanercept

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2006-12
Est. Completion 2009-09
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT00413400 record still lists

NCT00413400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00413400 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00413400 about?

NCT00413400 is a clinical study titled "Study of TNF-Antagonism in the Metabolic Syndrome (II)". This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.

What is the current status of trial NCT00413400?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2006-12. Estimated completion is 2009-09.

What interventions are being tested in trial NCT00413400?

The interventions under investigation include: Placebo (DRUG), Etanercept (DRUG).

Who is sponsoring clinical trial NCT00413400?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00413400's enrollment target sits among peer trials

40 1447th of 2000 higher than 465 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00413400, the US trial registry maintained by the National Library of Medicine. NCT00413400 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.